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Abstract 
The immunosuppressive individuals are highly prone to get afflicted with invasive opportunistic fungal infections such as Candidiasis, Aspergillosis, 
Histoplasmosis, Coccidioidomycosis, Blastomycosis, Penicilliosis, Cryptococcosis and Zygomycosis which are becoming a cause of concern to the mankind due 
to their high morbidity and mortality rates. The existing antifungal agents are not completely effective due to their severe side-effects and recurrent drug resistance 
in fungi. Hence, there is an urgent need to develop newer and better antifungal drugs. The enzyme Glucosamine-6-phosphate (G-6-P) synthase catalyzes the rate-
limiting step of the fungal cell-wall biosynthetic pathway and targeting it can inhibit the growth of the fungus. The present study attempts to investigate the 
inherent variations in functional domain viz. Glutaminase (GATase II) and Sugar Isomerising (SIS) of Glucosamine-6-phosphate (G-6-P) synthase enzyme of 
mycoses-causing fungi. These domains may be identified as probable active site(s). Multiple sequence alignment performed using ClustalX2 and construction of 
phylogenetic tree of individual domains by MEGA v5.0 helped in the analyses of several variable amino acid sites within the domains suggesting their vital role in 
the pathogenesis of the fungi. Further, the online server ConSurf implied that mostly, the highly conserved residues of the domains were functional and exposed on 
the surface of the active site, making it an easy target for the drugs. Consequently, variable analysis of functional domains of target implicated the importance of 
target specific drug discovery for the treatment of invasive fungal infections or mycoses. 
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Background: 
An increasing number of immunocompromised patients [1] suffering largely 
from AIDS, cancer and undergoing organ transplants or immunosuppressive 
therapy are getting afflicted with invasive fungal infections, better known as 
mycoses. Such infections viz. Candidiasis, Aspergillosis, Histoplasmosis, 
Coccidioidomycosis, Blastomycosis, Penicilliosis, Cryptococcosis and 
Zygomycosis are caused by fungi belonging to different phyla, i.e. 
Ascomycetes, Basidiomycetes and Zygomycetes. The disease management 
involves treatment with antifungal drugs, and even surgery at times [2]. 
However, drugs such as Amphotericin B, which is the first-line drug of choice 
for invasive mycoses is nephrotoxic and hepatotoxic. Besides, the fungi are 
acquiring recurrent resistance against the existing antifungal agents, rendering 
them less effective. Therefore, there is a rapid requirement for the development 
of effective antifungal drugs for mycoses at large, for which a potential drug 
target could be found in the housekeeping genes which are highly conserved 
throughout species and could be studied further to carry out thorough analyses 
of the catalytic active site before a lead compound can be selected by the drug 
discovery process.  
 
The enzyme, Glucosamine-6-Phosphate (G-6-P) synthase [EC 2.6.1.16] is 
ubiquitously present and highly conserved in mycoses-causing fungi. It is 
known to catalyze the rate-limiting step of the fungal cell-wall biosynthetic 
pathway and inhibiting it can delimit the growth of the fungus. The enzyme 
consists of two domains, the Glutaminase (GATase II) domain and the Sugar 
Isomerising (SIS) domain where the probable active site(s) can be identified. 
For instance, previous studies in E. coli have suggested the active sites to lie 
within the two domains of G-6-P synthase [3]. The drug discovery protocols 
frequently consider selecting the highly conserved functional motifs against 
which drugs could be designed. But the increasing ineffectiveness, toxicity and 
fungal resistance towards existing antifungal drugs have raised an issue to find 
inherent amino acid variations within the domains and its influence on the 
active site(s) for mycoses-causing fungi. The amino acid sequences of various 
mycoses-causing fungi were collected from various databases followed by their 
phylogenetic analysis subsequent to multiple sequence alignment and further 
detection of their functional residues. Consequently, this study will aid drug 
discovery for mycoses-causing fungi in the near future. The availability of 
sequenced fungal genomes has greatly contributed to this study. 
 
Methodology: 
Amino acid sequences of G-6-P synthase of mycoses-causing fungi as obtained 
from World Health Organization, listed in Table 1 (see Supplementary 
material) were retrieved from Broad Institute of MIT and Harvard fungal BIOINFORMATION  open access 
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database [4], NCBI fungal database [5] and The DOE Joint Genome Institute 
fungal database. A total of 20 sequences were retrieved and compiled from 
these databases. The online server PFAM was used to investigate protein 
domains present within the enzyme. Subsequently, the sequences were 
manually separated according to the domains predicted by PFAM. Further, the 
protein sequences were aligned using the offline software CLUSTALX2 [6]. 
MEGA v5.0 [7] was employed to infer the evolutionary history using the 
Neighbour-Joining method. The bootstrap consensus tree inferred from 1000 
replicates is taken to represent the evolutionary history of the taxa analyzed. 
The evolutionary distances were computed using the Poisson correction 
method. All positions containing gaps and missing data were eliminated. 
Additionally, the functionally important amino acids were identified using 
ConSurf webserver. 
 
 
Figure 1: ConSurf color-coded MSA of the first GATase II domain of G-6-P 
synthase using amino acid sequences of mycoses-causing fungi. The pink to 
blue color gradient represent highly conserved to variable regions of the 
domain. The yellow marked amino acids indicate that the calculation for the 
particular site was performed on less than 10% of the sequences. 
 
Discussion: 
The online server PFAM yielded the inherent protein domains lying within G-
6-P synthase viz. two GATase II domains and two SIS domains in mycoses-
causing fungi where the probable active sites are found. Subsequently, the 
MSA results (Figure 1 showing partial results) obtained from ConSurf showed 
few variable sites within the highly conserved regions which are being 
investigated in the present study, along with the more evolutionary affected 
regions. The GATase II domains comprised 48 and 140 amino acid residues 
and the SIS domains comprised 127 and 146 residues. Position 18 of the first 
GATase II domain and position 51 of second SIS domain observed 
zygomycetous fungi having isoleucine replaced with a valine and valine 
replaced with isoleucine, respectively. Hence, for drugs targeting zygomycosis, 
it should be able to bind to these sites apart from the highly conserved residues 
for a better efficacy. At position 21 of the first GATase II domain, threonine 
has been replaced by asparagine in the case of C. albicans and C. dubliniensis. 
During analysis of the second GATase II domain, it was found out that lysine 
has taken the place of serine in all Candida species at position 24. Position 8 
and 123 has asparagine instead of serine and glycine instead of alanine, 
respectively for all Candida species except C. glabrata. Since, Candidiasis is 
the most prevalent antifungal infection which is mainly caused by C. albicans, 
it is possible that threonine, lysine, asparagine and glycine may play a pivotal 
role in the pathogenesis of Candida species. C. tropicalis and Cryptococcus 
neoformans do not encompass the first GATase II domain. Furthermore, the 
only commonality found between zygomycetes and basidiomycetes is at 
position 12 and 73 of the MSA of second GATase II domain, where methionine 
and valine replaced isoleucine, respectively and at position 38 of second SIS 
domain where isoleucine is present instead of valine. Sites 66 and 107 of 
second GATase II domain and sites 35, 70 and 72 of second SIS domain 
showed that all Aspergillus species share common residues with Penicillium 
species, H. capsulatum, Blastomyces and C. immitis. Aspergillosis has been 
known to be a fatal disease after Candidiasis, but it is not the case with 
Penicilliosis, Blastomycosis, Histoplasmosis and Coccidiomycosis; hence, 
these sites might not have a lethal role in the fungus. The first SIS domain is 
observed to be a highly conserved region among all species with no variability 
sites within the conserved regions. Hence, targeting this site can be upheld to 
the drugs’ efficacy. According to literature, cysteine 1 of G-6-P synthase in E. 
coli [3] and cysteine 2 of the same enzyme in Volvariella volvacea [8] have 
significant role in the enzyme catalysis. The online server ConSurf predicted 
the functional amino acid residues for R. oryzae RO3G_04247.3. Results reveal 
that cysteine residue at position 1 is highly conserved and exposed on the 
active site, making it easily targetable by drugs. Thus, it can be seen that 
conserved residues generally comprising the active site are mostly functional 
and central to drug binding.  
 
Figure 2: A Neighbour-Joining phylogenetic tree from amino acid sequences 
of (a) first GATase II domain and (b) first SIS domain of mycoses-causing 
fungi, constructed using MEGA v5.0 with 1000 bootstrap replicates. The 
evolutionary distances were computed using the Poisson correction method. All 
positions containing gaps and missing data were eliminated. 
 
Moreover, phylogenetic tree for individual domains was constructed as well 
(Figure 2) using MEGA v5.0 with 1000 bootstrap replicates which helped in 
understanding the evolutionary relationship of the various functional domains 
in mycoses-causing fungi. All the four trees constructed individually for each 
domain grouped Candida species together, with C. albicans and C. dubliniensis 
being closer to each other than the rest suggesting that all the Candida species 
could be targeted with one effective drug. A. niger 2 lies quite separately from 
the rest of the Aspergillus species, implying that it might be more resistant to 
antifungal drugs. Consequently, variations within the G-6-P synthase of A. 
niger 2 could reveal answers to increasing resistance to drugs, and accordingly, 
newer lead compounds could be designed. Zygomycetes, R. oryzae and M. 
circinelloides are grouped at the bottom of the tree and single drug needs to be 
developed to be effective against zygomycetes causing zygomycosis. 
 
Conclusion: 
Domain variability analyses of G-6-P synthase in mycoses-causing fungi were 
carried out because of increasing fungal resistance towards antifungal drugs, 
and consequently, there is a requirement for better and more effective drugs. 
The current study was aimed to investigate the variable regions within the 
conserved domains of the enzyme which might affect its active site and 
subsequently, alter the drug binding, since a single amino acid residue can 
augment or reduce the drug binding to the target enzyme. Our study revealed 
specific residues which might play significant roles in the fungal pathogenesis. 
Hence, variant analyses implicate the binding efficacy between the receptor 
and ligand and direct the new direction in effective drug development through 
pharmacophore modelling and structure-activity relationships. The work may BIOINFORMATION  open access 
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be enhanced by incorporating the ensemble approach of variability analysis on 
target site for mycoses-causing fungi. 
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Supplementary material: 
 
Table 1: List of mycoses-causing fungi used in the present study as obtained from World Health Organization 
Fungi name  Database ID  Protein size 
Rhizopus oryzae_1  RO3G_04247.3 
(Broad institute of Harvard and MIT) 
688 aa 
Rhizopus oryzae_2  RO3G_14807.3 
(Broad institute of Harvard and MIT) 
688 aa 
Mucor circinelloides  JGI ID: 50270  688 aa 
Phycomyces blakesleeanus   JGI ID: 37053  692 aa 
Candida albicans  NCBI-GeneID: 3636557  713 aa 
Candida tropicalis  NCBI-GeneID: 8301698  686 aa 
Candida dublinieasis  NCBI-GeneID: 8046592  711 aa 
Candida glabrata  NCBI-GeneID: 2890320  723 aa 
Aspergillus nidulans  NCBI-GeneID: 2872076  898 aa 
Aspergillus fumigatus  NCBI-GeneID: 3508772  694 aa 
Aspergillus flavus  NCBI-GeneID: 7919759  693 aa 
Aspergillus niger_1  NCBI-GeneID: 4990250  694 aa 
Aspergillus niger_2  NCBI-GeneID: 4980582  702 aa 
Aspergillus clavatus  NCBI-GeneID: 4705325  694 aa 
Coccidioides immitis  NCBI-GeneID: 4562337  716 aa 
Cryptococcus neoformans  NCBI-GeneID: 3256900  706 aa 
Penicillium chrysogenum  NCBI-GeneID: 8315998  694 aa 
Penicillium marneffei  NCBI- GeneID: 212543329  694 aa 
Blastomyces dermatitidis  BDBG_01706.1 694  aa 
 
    
 
 